Molecular imaging of tumors with nanobodies and antibodies: timing and dosage are crucial factors for improved in vivo detection by Bannas, B. et al.
Molecular imaging of tumors with nanobodies
and antibodies: Timing and dosage are crucial
factors for improved in vivo detection
Peter Bannasa*†, Alexander Lenza,b†, Valentin Kunicka,b, Lennart Wella,b,
William Fumeya,b, Björn Rissiekb,c, Friedrich Haagb, Joanna Schmida,b,
Kerstin Schützea,b, Anna Eichhoffb, Martin Trepeld, Gerhard Adama,
Harald Ittricha and Friedrich Koch-Nolteb
The utility of nanobodies and conventional antibodies for in vivo imaging is well known, but optimum dosing and
timing schedules for one versus the other have not been established. We aimed to improve speciﬁc tumor imaging
in vivo with nanobodies and conventional antibodies using near-infrared ﬂuorescence (NIRF) imaging. We used
ARTC2 expressed on lymphoma cells as a model target antigen. ARTC2-speciﬁc nanobody s+16a and conventional
antibody Nika102 were labeled with NIRF-dye AF680. In vivo NIRF-imaging of ARTC2-positive and ARTC2-negative
xenografts was performed over 24h post-injection of 5, 10, 25, or 50μg of each conjugate. Speciﬁc target-binding
and tissue-penetration were veriﬁed by NIRF imaging ex vivo, ﬂow cytometry and ﬂuorescence microscopy. NIRF-
imaging of s+16a680 in vivo revealed a six times faster tumor accumulation than of Nika102680. Using 50μg of
s+16a680 increased the speciﬁc signals of ARTC2-positive tumors without increasing background signals, allowing
a tumor-to-background (T/B) ratio of 12.4 ± 4.2 within 6 h post-injection. Fifty micrograms of Nika102680 increased
speciﬁc signals of ARTC2-positive tumors but also of ARTC2-negative tumors and background, thereby limiting
the T/B ratio to 6.1 ± 2.0. Ten micrograms of Nika102680 only slightly reduced speciﬁc tumor signals but dramatically
reduced background signals. Ex vivo analyses conﬁrmed a faster and deeper tumor penetration with s+16a680. Using
nanobody s+16a allowed same-day imaging with a high T/B ratio, whereas antibody Nika102 gave optimal imaging
results only 24 h post injection. Nanobody s+16a required a high dose, whereas antibody Nika102 had the best T/B-
ratio at a low dose. Therefore, timing and dosage should be addressed when comparing nanobodies and conven-
tional antibodies for molecular imaging purposes. Copyright © 2015 John Wiley & Sons, Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
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1. INTRODUCTION
In vivo molecular imaging focuses on the non-invasive detection
and characterization of target structures with speciﬁc probes
(1,2). Based on their unmatched binding speciﬁcity and afﬁnity,
monoclonal antibodies are considered the most speciﬁc probes
for targeted imaging (3–5). However, their preclinical and clinical
utility is limited due to their relatively poor and slow tissue pen-
etration, slow clearance from circulation, and long retention in
non-targeted tissues (6). These characteristics impair their
signal-to-background ratio (7). The development of new contrast
agents and novel engineered forms of antibodies, such as
diabodies, minibodies, single-chain variable fragments, and
nanobodies, has triggered a new wave of antibody-based imag-
ing approaches (3,5,6,8). Among these, nanobodies are the
smallest available antigen-binding fragments derived from cam-
elid heavy-chain-only antibodies (9,10). With only ~15–18 kDa,
these small antibody fragments are soluble, very stable and are
renally cleared from the circulation (9,11). These properties make
them particularly suited for speciﬁc and efﬁcient targeting of
tumor antigens in vivo (12–20).
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Recent studies have shown that nanobodies allow higher
tumor-to-background (T/B) ratios than conventional antibodies
in molecular imaging applications in vivo (17,19). However, the
T/B ratio depends on two parameters: speciﬁc binding of the
antibody-construct leading to accumulation in the tumor as well
as clearance of unbound constructs from the body. Both param-
eters depend on the molecular size of the probe. A small
nanobody (~15 kDa) is expected to penetrate tumor tissue more
rapidly than a larger conventional antibody (150 kDa). In turn,
clearance of a nanobody via the kidney is fast, leading to short
circulation times with a half-life of only ~1.5 h, as compared to
days or weeks of conventional antibodies (3,11,21). Therefore,
the comparison of two differently sized antibody-constructs for
speciﬁc imaging of targets in vivo has to take into account the
different kinetics of tumor accumulation and elimination from
the circulation (11). This means that different imaging time
points have to be investigated to determine best imaging condi-
tions for each individual antibody construct. Moreover, different
doses of the antibodies have to be compared, since higher doses
may increase both speciﬁc and unspeciﬁc signals alike, thus
reducing the maximum achievable T/B ratio.
There are only few studies directly comparing nanobodies and
conventional antibodies for in vivo molecular imaging. Moreover,
these studies did not optimize the doses of the conventional anti-
body and some used high doses of up to 100μg antibody per ani-
mal (17,19). The high dosage inevitably leads to an excess of free
circulating antibodies. When assessing T/B ratios based on the
region of interest (ROI) in near-infrared ﬂuorescence (NIRF) imaging
experiments, the signal of the normal tissue serving as “back-
ground” will increase by the circulating antibodies. This results in
lower T/B ratios of antibodies compared to nanobodies, not due
to differences in speciﬁc signal, but due to higher unspeciﬁc back-
ground signal. Moreover, these excess antibodies are all prone to
non-speciﬁc accumulation in target antigen-negative tumors by
the enhanced permeability and retention (EPR) effect (22,23). Apart
from kinetics and dosage, an intraindividual assessment of antigen-
positive and -negative xenografts would enable a direct comparison
of speciﬁc and unspeciﬁc signals due to the EPR effect. In addition, a
comparative ex vivo analysis of explanted tumors would further
determine the speciﬁcity observed in imaging experiments in vivo
to optimize imaging conditions of differently sized constructs.
Therefore, we performed a direct NIRF-imaging comparison of a
single-domain nanobody (s+16a, 17 kDa) and a monoclonal anti-
body (Nika102, 150 kDa) directed to the same target to improve spe-
ciﬁc in vivo NIRF-imaging in a lymphoma xenograft model. S+16 is a
nanobody (single variable domain) derived from a heavy-chain-only
llama antibody. Nika102 is a conventional monoclonal antibody (rat
IgG2a kappa, composed of two heavy chains and two light chains)
(Fig. 1A). Compared to mAb Nika102, nanobody s+16a exhibits a
lower binding afﬁnity (40nM vs. 5 nM) and shorter in vivo blood
half-life (2 h vs. 8 days) (11,24,25). The model target antigen
ADP-ribosyltransferase ARTC2 is expressed on the surface of lym-
phoma cells (25–29). Beyond assessment of the advantages and dis-
advantages of nanobodies and conventional antibodies, this study
was designed to determine the speciﬁc requirements, such as
timing and dosage, for optimum imaging of tumors.
2. RESULTS
Purity of s+16a and Nika102 before and after conjugation to
AF680 was conﬁrmed (Fig. 1B). Assessment of binding afﬁnities
showed less than 10% reduction in labeling efﬁciencies upon
overnight incubation in serum (Fig. 1C). Competition studies
revealed that nanobody s+16a and antibody Nika102 recognize
different epitopes of ARTC2 (Fig. 1D). Internalization studies
showed prominent staining of the cell surface upon incubation
of cells at 4°C with both constructs. Upon incubation at 37°C,
most of the labeled nanobody s+16a680 and antibody Nika102680
remained on the cell surface. Patchy cytosolic staining with both
constructs after incubation for 24 h at 37°C indicates that a
fraction of ﬂuorescent label is internalized during prolonged
incubation at 37°C (online Supplementary Fig. 1).
2.1. In vitro NIRF-imaging experiments
Flow cytometry showed speciﬁc labeling of ARTC2-transfected
DC27.10 lymphoma cells with s+16a680 and Nika102680, but not
of parental ARTC2-negative DC27.10 cells (Fig. 2A). Staining with
s+16a680 yielded lower ﬂuorescence intensities (MFI = 15100
± 1700) as compared to Nika102680 (MFI = 73300± 1500), which
reﬂects the lower labeling efﬁciency with ﬂuorochrome AF680
of s+16a compared to Nika102 (0.3 dyes/molecule for s+16a as
compared to 2.0 dyes/molecule for Nika102). To provide a basis
for the subsequent in vivo and ex vivo xenograft experiments, we
further analyzed the same cells in vitro by ﬂuorescence microscopy
and with the NIRF-imaging system. Labeling of s+16a and Nika102
with AF680 not only allowed detection of ARTC2-positive cells with
ﬂuorescence microscopy but also semi-quantitative analyses with
the NIRF-imaging system intended for in vivo experiments (Fig. 2B,
C). ARTC2-negative cells showed no detectable signals using either
technique. As shown by ﬂow cytometry, the ﬂuorescence signal
detected from ARTC2-positive cells with the NIRF-imaging system
was lower when labeled with s+16a680 (radiant efﬁciency= 5.1
± 2.1× 107) than with Nika102680 (radiant efﬁciency= 9.4
± 2.5× 107). Signals from ARTC2-negative cells were more than
10 times lower than those of ARTC2-positive cells for s+16a680
(radiant efﬁciency= 3.0± 1.5× 106) as well as for Nika102680
(radiant efﬁciency= 3.5± 2.3× 106).
2.2. NIRF-imaging experiments in vivo
Next, we aimed to evaluate the suitability of Alexa-680-
conjugated nanobodies and antibodies for in vivo imaging of
ARTC2-positive tumors. Therefore, we intravenously injected
s+16a680 and Nika102680 into mice at four different doses (5, 10,
25, and 50μg) 7–9 days after subcutaneous injection of ARTC2-
positive and ARTC2-negative DC27.10 lymphoma cells on the
opposite ﬂanks of the same animals. The injected doses correspond
to 0.004, 0.009, 0.022, and 0.044mg of dye/kg for s+16a680 and to
0.003, 0.006, 0.016, and 0.032mg of dye/kg for Nika102680 for a
mouse of 24g. Imaging was performed before and at deﬁned
time-points over 24h after injection of the ﬂuorochrome
conjugates (Figs. 3 and 4 and Supplementary Fig. 1). The results
showed efﬁcient and speciﬁc labeling of ARTC2-positive tumors
with both constructs. When injected with Nika102680, the speciﬁc
signal in ARTC2-expressing tumors slowly increased over time,
whereas after injection of s+16a680, the signal was already strong
at early time points and declined over time (Fig. 3). Both
constructs showed higher signals of ARTC2-positive tumors with
increasing concentrations. At early time points after injection of
s+16a680, strong signals were observed also in the kidneys,
reﬂecting passage of the nanobodies through the renal ﬁltration
barrier. Note the high background signals of the entire animal
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Figure 1. Structure, purity, stability and competition study of ARTC2-speciﬁc AF680-conjugates. (A) Scheme of nanobody s+16a and mAb Nika102.
(B) Coomassie-stained gel overlaid by a corresponding NIRF image of unconjugated s+16a and Nika102 (lanes 1 and 3) and respective AF680-conjugates
(lanes 2 and 4) (1μg per lane of any given conjugate). (C) To asses the stability of the AF680-conjugates, conjugates were serially diluted and incubated
for 24 h either at 4°C in PBS or at 37°C in serum. Conjugates were then used to stain ARTC2-expressing lymphoma cells before analysis by ﬂow cytometry.
Fluorescence intensities of themean ± SD from three independent experiments are plotted. (D) ARTC2-expressing lymphoma cells were pretreatedwith PBS,
unlabeled s+16a or Nika102 before staining with ﬂuorochrome-conjugated Nika102, s+16a or isotype control antibodies and analysis by ﬂow cytometry.
Figure 2. Imaging of AF680-conjugates in vitro. Untransfected () and ARTC2-transfected (+) DC27.10 lymphoma cells were incubated with s+16a680
and Nika102680. (A) One aliquot of labeled cells (1 × 106) was subjected to ﬂow cytometry to quantify cell-bound AF680 conjugates. Mean ﬂuorescence
intensity of ARTC2 expression on lymphoma cells is plotted. Numbers indicatemean ± SD ﬂuorescence intensity of ARTC2-positive cells (grey histograms)
from three independent experiments. Unﬁlled histograms show isotype controls. (B) Another aliquot of labeled cells (1 × 105) was used for ﬂuorescence
microscopic analysis of speciﬁc ARTC2 labeling (red). Nuclei were counter-stained with DAPI (blue). The size bar indicates 10 μm. (C) A third aliquot of cells
(1 × 107) was transferred onto a 96-well plate for NIRF imaging in vitro. Results are representative of three independent experiments.
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after injection of 50μg of Nika102680 and the unspeciﬁc signals
of the negative tumor when using higher doses of Nika102680
(Figs. 3D and 4A).
The intermediate dose of 25μg showed lower speciﬁc signals
for both s+16a680 and Nika102680 as compared to 50μg and
higher speciﬁc signals as compared to 10μg (Supplementary
Fig. 2). The dose of 25μg also showed higher unspeciﬁc signals
in ART2-negative tumors for Nika102680 resulting in a lower
T/B-ratio as compared to 10μg. The lowest dose of 5μg showed
the lowest speciﬁc and unspeciﬁc signals for both constructs
with lowest resulting T/B ratios. In summary, the comparison of
different doses of AF680-conjugates showed best imaging
results with 50μg of s+16a680 and with 10μg of Nika102680 by
achieving highest speciﬁc signal intensities (s+16a680) and by
minimizing unspeciﬁc signals of ARTC2-negative tumors and
background while maintaining sufﬁcient speciﬁc signals
(Nika102680), thereby allowing for highest T/B-ratios.
Semi-quantitative ROI analyses conﬁrmed a rapidly increasing
T/B ratio of ARTC2-positive tumors after injection of s+16a680,
which reached a maximum of 12.4 ± 4.2 (50μg) and 4.7 ± 0.1
(10μg), respectively, already 4–6 h post-injection (Fig. 4B). The
T/B ratio of ARTC2-positive tumors detected with s+16a680 was
signiﬁcantly higher than of ARTC2-negative tumors throughout
2 h to 24 h post-injection. In contrast, the T/B ratio using
Nika102680 increased only slowly and reached its maximum of
8.7 ± 3.9 (10μg) and 6.1 ± 2.0 (50μg), respectively, not until 24 h
post-injection. In the case of Nika102680, the T/B ratio of
ARTC2-positive tumors was not signiﬁcantly higher than of
ARTC2-negative tumors until 8 h to 24 h post-injection due to
the high unspeciﬁc signal of ARTC2-negative tumors.
The need to evaluate different time points and different doses
when comparing differently sized antibodies for coherent NIRF-
imaging experiments is illustrated in Fig. 5. The direct compari-
son of the T/B ratios obtained by using either 10μg or 50μg of
each AF680-conjugate at different time points revealed that in
the case of s+16a680, signiﬁcantly higher T/B ratios can be obtained
with the higher concentration of 50μg 4 to 6h post-injection.
Interestingly, in Nika102680-injected mice, a signiﬁcant difference
between the two dosing regimens was seen only after 24h, and,
as shown above, with a higher T/B ratio obtained by the lower
concentration of 10μgNika102680. Based upon these observations,
the following ex vivo experiments were performed at the optimum
imaging time points and optimum probe concentrations of 6 h
and 50μg for s+16a680 and of 24h and 10μg for Nika102680.
2.3. NIRF-imaging experiments ex vivo
ARTC2-positive and ARTC2-negative tumors were explanted 6 h
and 24 h post-injection to quantify tumor-associated ﬂuores-
cence and T/B ratios in the absence of potentially confounding
signals from other tissues. The results of NIRF-imaging ex vivo
reﬂect those of the in vivo experiments (Fig. 6). Both AF680 conju-
gates showed high signals from ARTC2-positive tumors, which
decreased for s+16a680 and increased for Nika102680 over time
(Fig. 6A). Signals of ARTC2-positive tumors were signiﬁcantly
higher than of ARTC2-negative tumors in the case of s+16a680
only at 6 h (p< 0.001) and in the case of Nika102680 only at 24 h
(p< 0.05) post-injection. Note the low unspeciﬁc signal of
ARTC2-negative tumors after injection of s+16a680 at both time
points, as compared to the high unspeciﬁc signal of ARTC2-
negative tumors after injection of Nika102680. In the case of
s+16a680, the T/B ratio of dissected ARTC2-positive tumors was
signiﬁcantly higher than that of ARTC2-negative tumors at both
time points, 6 h and 24h post injection (p< 0.01 and p< 0.05,
respectively) (Fig. 6B). As for the absolute signal intensities,
Nika102680 culminated in a signiﬁcantly higher T/B ratio of posi-
tive tumors as compared to negative tumors only 24 h post-
injection (p< 0.05). Note the much higher T/B ratio (61.4 ± 30.9)
of ARTC2-positive tumors 24 h post-injection of Nika102680 as
compared to the maximum achievable T/B ratio of s+16a680
Figure 3. Comparison of different doses and time points for speciﬁc NIRF imaging in vivo. Seven to nine days after subcutaneous implantation of
ARTC2-positive (+) and ARTC2-negative (-) lymphomas, s+16a680 (A, B) and Nika102680 (C, D) were injected intravenously at a dose of 10 μg (A, C) or
50 μg (B, D), respectively. NIRF imaging was performed before and 1, 2, 4, 6, 8, 12, and 24 h after injection. Signal intensities of all injected mice and
imaging time points are all equally leveled to allow direct and fair visual comparison. Results are representative of at least three independent experi-
ments. Levels of statistical signiﬁcance are indicated by asterisks (* = p< 0.05, ** = p< 0.01, *** = p< 0.001).
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Figure 4. Radiant efﬁciency and T/B ratio of ARTC2-positive and ARTC2-negative tumors in vivo. S+16a680 and Nika102680 were injected into ARTC2-
positive and ARTC2-negative tumor-bearing mice at a dose of 10 μg (upper panels) or 50 μg (lower panels), respectively. NIRF imaging was performed
at different time points after injection and ROIs were drawn around tumors and normal tissue (hind leg) for semi-quantitative analyses. (A) Radiant
efﬁciencies and (B) calculated T/B ratios of ARTC2-positive and ARTC2-negative tumors as well as background signals are plotted as a function of time.
Data are presented as mean ± SD from at least three independent experiments for each group. Levels of statistical signiﬁcance are indicated by asterisks
(* = p< 0.05, ** = p< 0.01, *** = p< 0.001).
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(27.8 ± 9.6) after 6 h in the absence of confounding signals from
normal tissue.
Biodistribution analyses of spleen, lungs, liver, kidneys, stomach,
ileum, and muscle revealed an overall decline of signal in-
tensities at 24 h as compared to 6 h (Fig. 7A). At both time
points, 6 h and 24 h post-injection, the highest unspeciﬁc
organ-to-background ratios were observed for the liver in the
case of Nika102680 and for the kidneys in the case of s+16a680
(Fig. 7B). Interestingly, in the case of Nika102680, at 6 h
post-injection the second highest organ-to-background ratio
was observed for the ARTC2-negative tumor and at 24 h the
ARTC2-negative tumor showed even the highest unspeciﬁc sig-
nals when compared to other organs.
2.4. Flow cytometry and ﬂuorescence microscopy ex vivo
Next, we determined possible causes of the unspeciﬁc signals
from normal tissue after injection of Nika102680 in vivo (Figs. 3D,
4A) as well as from ARTC2-negative tumors in vivo and ex vivo
(Figs. 4A and 6). Therefore, we performed ﬂow cytometry ex vivo
to quantify levels of unbound AF680-conjugates in serum and of
cell bound AF680-conjugates on dispersed cells from the
explanted tumors (Fig. 8). Serum samples showed little, if any,
detectable circulating s+16a680 at 6 h and 24 h post-injection
(Fig. 8A). In contrast, mice that had been injected with
Nika102680 showed signiﬁcantly higher levels of unbound circu-
lating Nika102680 in serum at both time points, which somewhat
decreased over time, but were still present in excess 24 h post-
injection. Urine analyses revealed high levels of s+16a680, partic-
ularly 6 h post-injection, but little, if any, Nika102680 (data not
shown).
Flow cytometry of dispersed cells from xenografts dissected
6 h and 24 h post-injection showed speciﬁc labeling of ARTC2-
positive lymphoma cells with both AF680-conjugates and no
unspeciﬁc labeling of ARTC2-negative tumor cells (Fig. 8B). As seen
with NIRF-imaging in vivo and ex vivo, labeling and speciﬁc signals
from ARTC2-positive tumors decreased over time after injection of
s+16a680, whereas signals of ARTC2-positive tumors from animals
injected with Nika102680 increased over time. Signals of cells
from ARTC2-positive tumors from animals injected with s+16a680
were higher than signals after injection of Nika102680 at 6 h post
injection, but lower at 24 h after injection.
Figure 5. Optimization of probe concentration and NIRF-imaging time point for maximal T/B ratio of s+16a680 and Nika102680 in vivo. T/B ratios
obtained from NIRF imaging of ARTC2-positive tumors are plotted as a function of time for mice injected with either 10 μg (white columns) or 50 μg
(grey columns) of (A) s+16a680 and (B) Nika102680, respectively. Fifty micrograms of s+16a680 showed a higher T/B ratio than 10 μg, which was signif-
icant 4–6 h post-injection. Nika102680 showed the opposite behavior, the lower dose yielded a higher T/B ratio than the higher dose, which became
signiﬁcant after 24 h. Data are presented as mean ± SD from three to seven independent experiments. Levels of statistical signiﬁcance are indicated
by asterisks (ns = p> 0.05, * = p< 0.05, ** = p< 0.01, *** = p< 0.001).
Figure 6. NIRF imaging ex vivo. ARTC2-positive (+) and ARTC2-negative () tumors of mice injected with 50 μg s+16a680 or with 10 μg Nika102680 were
explanted 6 h and 24 h post-injection in order to quantitate tumor-associated ﬂuorescence and T/B ratios using NIRF imaging in the absence of poten-
tially confounding signals from other tissues. (A) Radiant efﬁciencies of tumors and (B) T/B ratios are presented as mean ± SD from ﬁve independent
experiments.
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We further analyzed the distribution of injected AF680-
conjugates within explanted and cryosectioned tumors ex vivo by
confocal ﬂuorescence microscopy (Fig. 9). S+16a680 revealed
homogeneous and speciﬁc labeling of ARTC2-positive tumor cells
6 h post-injection, similar to the staining of these cells in culture
(Fig. 2B). In contrast, Nika102680 showed only weak staining of cells
in ARTC2-positive tumors after 6 h. Moreover, the monoclonal anti-
body showed staining evidently not associated with tumor cells in
both ARTC2-positive and ARTC2-negative tumors (Fig. 9A, arrow).
3. DISCUSSION
The utility for both nanobodies and conventional antibodies for
in vivo imaging is well established, but optimum dosing and
timing schedules for one versus the other have not been
determined so far. Here, we used NIRF-dye AF680-conjugated
nanobodies and conventional monoclonal antibodies directed
at the same target on lymphoma cells for a direct comparison
of in vivo and ex vivo analyses. We showed that nanobodies are
well suited as diagnostic tools for rapid and speciﬁc in vivo detec-
tion of lymphomas, with superior tissue penetration compared
to conventional antibodies and signiﬁcantly higher T/B ratios
when performing same-day imaging in vivo. In addition, our
experiments revealed that at later time points the T/B ratio of
conventional antibodies can be improved by using lower doses
of antibody conjugates.
In vitro, both, nanobody s+16a680 and antibody Nika102680
bound speciﬁcally to ARTC2-positive lymphoma cells with no
unspeciﬁc labeling of ARTC2-negative cells (Fig. 2). Albeit that
Nika102680 showed stronger signals in vitro, s+16a680 allowed a
faster and more speciﬁc detection of ARTC2-positive xenografts
in vivo (Figs. 3 and 4). Apart from the different kinetics for best
tumor visualization in vivo, the major drawback of Nika102680
at higher doses (50μg) was the high unspeciﬁc signal originating
not only from normal tissues (causing ﬂuorescence signals from
the entire mouse), but also from ARTC2-negative tumors (Fig. 4).
This apparently insufﬁcient T/B ratio could be improved by using
a lower dose (10μg) of Nika102680, resulting in dramatically
reduced signals of normal tissues and ARTC2-negative tumors
and only slightly decreased speciﬁc signals of ARTC2-positive
tumors (Fig. 5). In contrast, increasing the dose of s+16a680
caused stronger signals of ARTC2-positive tumors but not of
normal tissue or ARTC2-negative tumors.
NIRF imaging of dissected tumors ex vivo revealed the overall
strongest T/B ratio of ARTC2-positive tumors 24 h post-injection
Figure 7. Biodistribution analyses. At 6 h and 24 h post-injection of 50 μg s+16a680 or 10 μg Nika102680 mice were sacriﬁced and tumors and organs
were explanted. (A) Organ- and tumor-associated ﬂuorescence was quantiﬁed and (B) organ- and tumor-to-background ratios were calculated using
NIRF imaging in the absence of confounding signals from other tissues. Signals from explanted muscle tissue served as background value to calculate
ratios. Radiant efﬁciencies of organs and tumors and organ- and tumor-to-background ratios are presented as mean ± SD from ﬁve independent
experiments.
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of Nika102680 in the absence of potentially confounding signals
from other tissues (Fig. 5). These in vivo and ex vivo NIRF-imaging
observations could be well explained by the results of ex vivo
ﬂow cytometric analyses for quantiﬁcation of injected AF680-
conjugates in serum (Fig. 8A). These showed high levels of
unbound and free circulating Nika102680 6 h and even 24 h
post-injection, even at the lower dose of 10μg, whereas after
the injection of 50μg of s+16a680 no unbound nanobodies were
Figure 8. Flow cytometric analyses of circulating and cell bound s+16a680 and Nika102680. (A) In order to determine a cause for the high background
signals and the unspeciﬁc signal of ARTC2-negative tumors post-injection of Nika102680, we analyzed serum to monitor levels of circulating unbound
AF680-conjugates. Mice bearing ARTC2-negative and ARTC2-positive tumors were injected intravenously with 50 μg s+16a680 and 10 μg Nika102680
and sacriﬁced 6 h and 24 h after injection. Serum at a dilution of 1:100 was used to label ARTC2-transfected lymphoma cells for ﬂow cytometric quan-
tiﬁcation of circulating intact AF680 conjugates. Fluorescence intensities of the mean ± SD from three independent experiments are plotted. Levels of
statistical signiﬁcance are indicated by asterisks (*** = p< 0.001). (B) To determine the level of injected conjugates speciﬁcally bound to tumor cells
both ARTC2-positive and ARTC2-negative tumors were dissected from the same animals. Single-cell suspensions were counterstained with anti-
CD45 and analyzed by ﬂow cytometry to quantify the amount of cell-bound AF680 conjugates. Means and standard deviations of ﬂuorescence inten-
sities (MFI) from three independent experiments are plotted.
Figure 9. Fluorescence microscopy ex vivo of ARTC2-positive and ARTC2-negative tumors. Confocal ﬂuorescence microscopy (40×) of tumor cryosec-
tions (A) 6 h and (B) 24 h post-injection of 50 μg s+16a680 and 10 μg Nika102680, respectively. Signal intensities of AF680-conjugates are displayed in red
and demonstrate the distribution within the tumor 6 h and 24 h after injection. Nuclei were counter-stained ex vivo with DAPI (blue) and blood vessels
were stained with anti-CD31488 (green). Nanobody s+16a680 revealed homogeneous and speciﬁc labeling of ARTC2-positive tumors readily within 6 h,
whereas Nika102680 showed weak staining after 6 h, which increased only after 24 h. At both imaging time points Nika102680 also showed unspeciﬁc
staining within or close to the tumor vasculature (arrow) of both ARTC2-negative and positive tumors. The size bar indicates 50 μm. These results are
representative of three independent experiments.
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detectable in serum at these time points. These results are in
accordance with a recent study in which we determined the phar-
macokinetics of s+16a680 and Nika102680 (11). It is conceivable,
that higher doses would further increase the amount of free cir-
culating Nika102680, and thereby further increase the observed
unspeciﬁc signals in vivo. Ex vivo ﬂow cytometric analyses of dis-
persed cells from dissected tumors showed speciﬁc staining of
ARTC2-positive tumor cells with both constructs but no unspe-
ciﬁc binding of injected AF680-conjugates to ARTC2-negative
lymphoma cells (Fig. 8B). These ﬁndings are consistent with
in vitro labeling experiments, which show prominent cell-surface
staining of ART2-positive tumor cells as well as some internalized
ﬂuorescence for both constructs after 24 h incubation at 37°C
(Supplementary Fig. 1). The higher staining intensity of ART2-
positive tumor cells with nanobody s+16a680 than with mAb
Nika102680 at 6 h post-injection likely reﬂects the higher injected
dose and faster tissue penetration of the nanobody. The lower
staining intensity of ART2-positive tumor cells with nanobody
s+16a680 than with mAb Nika102680 at 24 h post-injection likely
reﬂects the lower afﬁnity and renal elimination of excess
nanobody. The increase in staining intensity of mAb Nika102680
at 24 h versus 6 h likely reﬂects increasing accumulation in the
tumor from excess levels of circulating mAb. Fluorescence
microscopy completed the ex vivo imaging approach. In the case
of the nanobody s+16a, homogeneous staining of cells in
ART2C-positive tumor sections correlated well with the staining
of cells in vitro (Figs. 9A and 2B), conﬁrming that the nanobody
was able to reach even remote areas within the tumor after
6 h. In contrast, the monoclonal antibody showed only weak
staining of cells in ARTC2-positive tumors after 6 h. Moreover,
the monoclonal antibody showed staining within or close to
the tumor vasculature even in ARTC2-negative tumors (Fig. 9A),
providing a plausible explanation for the unspeciﬁc signals
during in vivo imaging. The better tissue penetration of the
nanobody s+16a at early time points is likely attributed to its
ability to cross the endothelial barrier more easily to reach its
target.
NIRF imaging of other organs ex vivo revealed high unspeciﬁc
signals for the liver in the case of Nika102680 and for kidneys in
the case of s+16a680. High signals in the kidney at early time
points are consistent with renal ﬁltration and partial retention
of nanobody s+16a680 in the kidneys. High signals in the liver
for both constructs are consistent with hepatic elimination of
ﬂuorochromes. Note that at the time point of ex vivo analyses
(6 h and 24 h), the signals from kidneys had already decreased
dramatically as compared to the in vivo signals at 1 h and 2 h
post-injection, presumably by elimination of most of labeled
nanobody s+16a680 from the body via urination. Signals from
the kidneys even after 24 h likely reﬂect partial tubular resorption
of nanobodies and/or ﬂuorochromes.
As in previous studies, the results reported here emphasize
that molecular imaging with labeled nanobodies in vivo allows
rapid and speciﬁc same-day tumor imaging, including the possi-
bility of increasing the dose for optimized T/B ratios without
compromising speciﬁcity of marked tissues (12–15,17–19). Our
study also reveals, that in vivo molecular imaging using conven-
tional antibodies can be considerably improved by determining
the optimum dose of the injected large (and therefore not
renally cleared) antibodies. A ﬁvefold lower dose of conventional
antibody can almost double the T/B ratio. Recent studies,
comparing nanobodies and conventional antibodies for in vivo
molecular imaging neglected to optimize the dose of the
investigated conventional antibody and used very high doses
of up to 100μg per animal (17,19). This leads to an excess of
free-circulating antibodies, as we were able to show for mAb
Nika102680 in the present study. These excess antibodies are
prone to nonspeciﬁc accumulation in target-negative tumors
by the enhanced permeability and retention effect (EPR)
described earlier for conventional antibodies (22,23). It should
be noted, that the EPR effect also leads to an increased uptake
of antibodies in the target-positive tumors and may thereby con-
tribute to increase the speciﬁc signals at low antibody doses.
Taken together, thorough dose optimization of conventional
antibodies should be performed for in vivo imaging applications.
For nanobodies, in contrast, dose optimization seems to be
less of an issue, since any excess is renally cleared within 2 h
and thus unspeciﬁc accumulation in non-targeted tissue is mini-
mized. This allows same-day imaging and could be translatable
to the clinical setting. However, next-day imaging might be more
convenient in a clinical setting. Further, the cost efﬁciency might
be better for the antibody due to the lower dose required, even
though nanobodies can be produced at low costs in bacteria and
yeast (10).
A limitation of our study is that we did not optimize the
amount of ﬂuorescent dyes per antibody construct, which might
affect the maximum achievable signal for imaging. Another
improvement of the labeling strategy would have been the
site-speciﬁc conjugation of the NIRF dye, as recently described
by Kijanka et al., instead of random conjugation to primary
amine groups, which might affect binding afﬁnity (17). Another
limitation is that we injected ﬁxed doses of 5, 10, 25 and 50μg
of our constructs regardless of the weight of the animals, instead
of performing weight-adapted injections. The differences in
weight of individual mice (range 22.5–26.1 g) may explain some
of the observed signal variations within different dose groups.
The region chosen for “background” signal estimation also
inﬂuences the calculated T/B ratios. However, nanobody s+16a
and mAb Nika102 show different accumulations in different
abdominal organs and blood, precluding a fair and comparable
estimation of T/B ratios with these tissues. As an alternative, we
chose the hind limb and muscle, respectively, because this tissue
introduced less variation, even though it might underestimate
the systemic background.
In addition, further studies should investigate time points later
than 24 h post-injection (e.g. 48 h, 72 h). These might show a fur-
ther improvement of the maximum achievable T/B ratio using
the conventional antibody, as recently shown for Trastuzumab
by Kijanka et al. (17). A limitation of nanobodies in imaging is
the high confounding signal of the kidneys due to their renal
elimination, which is particularly prominent at early time points.
This confounding signal might limit the ability of nanobodies to
detect tumors located close to the kidneys. However, the renal
retention of nanobodies can be reduced by 45% upon
co-injection of gelofusine and lysine without reduced tumor
uptake, as reported by Gainkam et al. (30).
An intrinsic limitation when comparing llama-derived
nanobodies and conventional antibodies is the fact that they
bind to different epitopes of the target antigen, which might
inﬂuence antibody internalization, unspeciﬁc binding to other
sites or uptake by the reticular endothelial system, thereby
affecting blood half-life. However, the differences observed
here in terms of dose and timing for optimal imaging can
be mainly explained by the size difference of the nanobody
and the conventional antibody.
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An inherent technical limitation of NIRF imaging is its low pen-
etration depth of 7–10mm, which is particularly suited for imag-
ing of subcutaneous tumors but does not allow for imaging of
orthotopic tumors. However, even for subcutaneous tumors,
some spillover from abdominal organs such as kidneys or liver
cannot be excluded. Therefore, thorough ex vivo validation
experiments of explanted tumors and organs are mandatory.
Another limitation of NIRF imaging is the only semi-quantitative
assessment of biodistribution as compared to radionuclide-
mediated imaging. However, this limitation is compensated in
part by the suitability of NIRF-labeled probes for ex vivo valida-
tion experiments, that is, quantitative ﬂow cytometric assess-
ment of antibodies bound to tumor cells. Moreover, for the
principle aim of this study, that is, optimizing timing and dosing
of nanobodies and antibodies for imaging in vivo, the NIRF tech-
nique is well suited. Our results are in accord with a recent study
by Oliveira et al. using NIRF-labeled nanobodies (19). If desired,
nanobodies can also be radiolabeled for positron emission
tomography (PET) imaging of xenograft models. A recent study
that compared nanobodies and conventional antibodies for
PET imaging also came to the conclusion that nanobodies allow
same-day imaging with high tumor-to-background ratios (15).
4. CONCLUSIONS
Labeling of nanobody s+16a and antibody Nika102 with AF680
allowed validation of in vivo NIRF-imaging results with ex vivo
ﬂow-cytometry and ﬂuorescence-microscopy. For this reason, and
because it is nonradioactive, highly sensitive, inexpensive, and uses
comparatively easy-to-produce targeted probes, we advocate the
use of the NIRF-imaging technique for evaluation of new antibody
constructs in preclinical molecular imaging experiments.
Our comparative in vivo and ex vivo analyses revealed that the
speciﬁc contrast between tumor and normal tissue is more im-
portant than the absolute amount of conjugate that reaches
the tumor. Moreover, our study conﬁrmed that timing and
dosage signiﬁcantly inﬂuence speciﬁc and unspeciﬁc in vivo
NIRF-imaging signals of s+16a680 and Nika102680. Nanobody
s+16a allowed same-day imaging with high tumor-to-
background ratio, whereas antibody Nika102 gave optimal imag-
ing results only 24 h post-injection. Nanobody s+16 required a
high dose while antibody Nika102 had the best tumor-to-
background ratio at a low dose. Therefore, timing and dosage
should be addressed when using nanobodies and conventional
antibodies for molecular imaging purposes.
5. EXPERIMENTAL
5.1. Cell lines and mice
ARTC2-transfected and untransfected DC27.10 murine lym-
phoma cells were cultured as described previously (26). The
closely related ARTC2.1 and ARTC2.2 T cell GPI-anchored cell sur-
face ecto-enzymes are encoded by tandem genes. The study was
performed with reagents speciﬁc for ARTC2.2, for better legibility
we use the term ARTC2. Tumor xenograft experiments were con-
ducted using athymic nude mice (NMRI-Foxn1nu) weighting 24.0
± 1.4 g (range 22.5 to 26.1 g). Mice were obtained from Charles
River Laboratories (Sulzfeld, Germany). Experiments were
performed in accordance with international guidelines on the
ethical use of animals and were approved by the local animal
welfare commission.
5.2. Generation of AF680-conjugates
Generation and puriﬁcation of ARTC2.2-speciﬁc nanobody s+16a
(~17 kDa) and of monoclonal antibody Nika102 (150 kDa) were
described previously (24,25). S+16a carries C-terminal His6x
and c-Myc epitope tags and has a calculated size of 17.4 kDa
(25). Nanobody s+16a and antibody Nika102 were conjugated
to the ﬂuorescent dye AlexaFluor-680 (AF680) (Molecular Probes,
Carlsbad, CA, USA) (excitation wavelength = 679 nm, emission
wavelength = 702 nm) and number of dye molecules per probe
were calculated using molar extinction coefﬁcients of
15720 cm1M1 and 203000 cm1M1, respectively. Purity of
antibody constructs before and after conjugation to AF680 was
assessed by SDS-PAGE size fractionation and Coomassie brilliant
blue gel stain as described previously (11). Binding afﬁnities as
well as stability during overnight incubation at 37°C in serum
were assessed by serial dilution of probes and ﬂow cytometric
analyses of labeled DC27.10 cells. Competition studies were per-
formed to evaluate whether s+16a and Nika102 recognize dis-
tinct or overlapping epitopes. ARTC2-transfected DC27.10 cells
were pretreated with phosphate buffered saline (PBS), unlabeled
s+16a (5μg/100μL) or unlabeled Nika102 (5μg/100μL) for
20min at 4°C before exposure to AF680-conjugated Nika102
(0.2μg/100μL), s+16a (0.2μg/100μL) or isotype control antibod-
ies for 20min and analysed by ﬂow cytometry. Internalization
studies were performed by staining of DC27.10 ARTC2 cells with
s+16a680 Nika102680 for 30min on ice and washed. Cells were
further incubated in cell culture medium at 4°C for 2 h or at
37°C for 2 and 24 h before ﬁxation in 2% PFA, counterstaining
with Hoechst 33428, and analysis by ﬂuorescence microscopy.
5.3. In vitro analyses
For in vitro ﬂow-cytometric analyses, 1 × 106 untransfected or
ARTC2-transfected DC27.10 cells were stained with s+16a680 or
Nika102680 (1μg/μL) or control antibodies for 30min at 4°C. Cells
were washed twice and analyzed by ﬂow cytometry on a FACS
Canto II (BD Biosciences, Becton Dickinson, Franklin Lakes,
USA). Dead cells were excluded after staining with propidium
iodide. Flow cytometry data was analyzed with FlowJo 9.3 soft-
ware (Tree Star Inc, Ashland, OR, USA).
For in vitro ﬂuorescence microscopy, 1 × 105 untransfected
or ARTC2-transfected DC27.10 cells were stained with either
s+16a680, Nika102680 or control antibodies as described above.
Cells were suspended in a volume of 0.2mL of PBS and
centrifuged (CytoSpin, Shandon, Pittsburgh, PA, USA) onto micro-
scope slides at 800 rpm for 5min. Cells were ﬁxed in acetone for
10min, washed twice in PBS, and mounted with Mowiol-DAPI
(Molecular Probes, Carlsbad, CA, USA). After air-drying for 24 h,
slides were analysed with an inverted microscope (Axiovert
200m, Zeiss, Goettingen, Germany) with excitation of 665 nm
and emission of 725 nm. Images were analyzed with ImageJ soft-
ware (NIH, Bethesda, Maryland, USA).
For NIRF imaging in vitro, 1 × 107 untransfected or ARTC2-
transfected DC27.10 cells were stained with either, s+16a680,
Nika102680 or control antibodies as described above. Cells were
sedimented on a black 96-well plate (Nunc, Waltham, Massachusetts,
USA). Measurements were performed with a small-animal
NIRF-imaging system (IVIS-200, Caliper Life Sciences, Hopkinton,
Massachusetts, USA) using ﬂuorescent ﬁlter sets of 515–665nm
for excitation, 695–770nm for emission, and 580–610nm for
background subtraction with a 512×512-pixel matrix size
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(15×15μm/pixel). Images were analysed semi-quantitatively by
placing a region of interest (ROI) on individual wells. Total radiant
efﬁciency was calculated with Living Image 4.2 software (Caliper
Life Sciences).
5.4. NIRF imaging in vivo
Prior to NIRF imaging in vivo, 8–10-week-old mice were kept on
an alfalfa-free diet for 7 days to reduce autoﬂuorescence of the
intestine. For generation of tumor xenografts of comparable size,
mice were subcutaneously injected at their back on the right
side with 1.5 × 106 ARTC2-transfected cells and on the left side
with 0.5 × 106 untransfected cells in a mix of 0.1mL RPMI me-
dium and 0.1mL Matrigel (BD Biosciences, Becton Dickinson,
Franklin Lakes, USA). The different number of cells has been used
to take into account the different growth rates of transfected
and untransfected cells. After 7–9 days, when tumors reached
~8mm in diameter, nanobody s+16a680 or conventional anti-
body Nika102680 was injected intravenously via the tail vein in a
volume of 200μL. NIRF imaging was performed before injection
and 1, 2, 4, 6, 8, 12, and 24 h after injection. Initial studies showed
that earlier time points did not yield useful diagnostic
information due to high unspeciﬁc signals and were therefore
not assessed. Experiments were performed with four doses of
each AF680-conjugate: 5μg, 10μg, 25μg, and 50μg. This
corresponded to 0.1μg, 0.2μg, 0.45μg and 0.9μg of injected
dye for nanobody s+16a and 0.06μg, 0.12μg, 0.3μg, and 0.6μg
of injected dye for monoclonal antibody Nika102.
For NIRF imaging in vivo, mice were anesthetized with
isoﬂuorane and positioned in the imaging chamber of the
small-animal NIRF-imaging system using the same ﬁlter settings
as described above. After qualitative imaging in vivo, quantita-
tive analyses were performed by placing ROIs around the
ARTC2-positive tumors, the ARTC2-negative tumors (negative
control) and the hind limb (background signal). Even though
the signal of the hind limb might underestimate the systemic
background, we chose the hind limb because this tissue intro-
duces less variation than abdominal organs or blood.
Total radiant efﬁciency was determined with Living Image 4.2
software (Caliper Life Sciences). Tumor-to-background ratio was
calculated by dividing the tumor uptake value by the back-
ground value determined from the hind limb.
5.5. Ex vivo analyses
For ex vivo validation of in vivo measurements, animals were
sacriﬁced 6 h or 24 h post-injection. ARTC2-positive and ARTC2-
negative tumors and organs (spleen, lungs, liver, kidneys, stom-
ach, ileum and muscle) were dissected. Biodistribution analysis
was performed using NIRF imaging ex vivo as described by
Bannas et al. (11). Total radiant efﬁciency of organs and tumors
was determined and organ- and tumor-to-background ratio
was calculated by dividing the tumor uptake value by the back-
ground value determined from explanted muscle tissue. Even
though the signal of muscle might underestimate the systemic
background, we chose muscle because this tissue introduces less
variation than abdominal organs or blood.
For ex vivo ﬂuorescence microscopy, one half of each har-
vested tumor was ﬁxed in 4% paraformaldehyde over night,
placed in 30% sucrose for 24 h and frozen on dry ice in Tissue-
Tek® OCT™ (Sakura Finetek, Alphen, The Netherlands). Sections
of 8μmwere prepared using a Reichert-Jung Ultracut microtome
(Reichert-Jung, Wien, Austria). Tumor cryosections were stained
with DAPI (Molecular Probes, Carlsbad, CA, USA) to visualize
nuclei and CD31 (M-20, Santa Cruz, Heidelberg, Germany) to visual-
ize vessels. Fluorescence microscopy analysis was performed
using a Leica TCS SP5 confocal microscope (Leica Camera AG,
Solms, Germany). A HeNe 633nm laser was used for excitation
of AlexaFluor680. Image analysis was performed using Leica
LAS (Leica) and ImageJ software (NIH, USA).
For ﬂow cytometry ex vivo, the other half of each tumor was
dissected and passed through a 70μm cell strainer to obtain
single-cell suspensions. Dispersed cells were counterstained with
pan leukocyte marker anti-CD45 (Clone 30-F1, eBioscience, San
Diego, CA, USA) and Paciﬁc Orange-NHS dye (Invitrogen, Grand
Island, NY, USA) for live/dead staining. Labeling efﬁciency of
ARTC2 by the injected AF680-conjugates was quantiﬁed by ﬂow
cytometry. For quantiﬁcation of free circulating AF680-
conjugates, serum was collected and used in a volume of
100μL (1:100 dilution) for labeling 1 × 106 ARTC2-expressing
DC27.10 cells with subsequent ﬂow cytometry.
5.6. Statistical analysis
Data are presented as mean± SD. Statistical analysis was per-
formed using two-way ANOVA with Bonferroni’s post-test analyses
to evaluate differences between the two independent variables
from experiments presented in Figs. 4 and 5. One-way ANOVA with
Bonferroni’s post-test analyses was performed to evaluate the
signiﬁcance of differences between four groups shown in Figs. 6
and 7A. P< 0.05 indicates statistical signiﬁcance. Statistical
analysis was performed using Prism 5, Graph Pad Software and
Excel, Microsoft.
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